Introduction
============

Thyroid cancer is the most common endocrine system malignancy and accounts for \~1% of all cancer diagnoses, with an incidence that increases each year ([@b1-ol-0-0-6694]). Among thyroid malignancies, papillary thyroid cancer (PTC) is the most common histological type, accounting for 80--85% of all thyroid cancer and presenting with a 10-year survival rate of \>90% ([@b2-ol-0-0-6694]). PTC is not a unitary carcinoma; this malignancy includes several sub-histological variants, including classical variant PTC (CVPTC) and follicular variant PTC (FVPTC). Tall cell, diffuse sclerosing and poorly differentiated PTC subtypes are categorized as aggressive variant PTC (AVPTC). Although patients with PTC typically demonstrate an excellent prognosis, cervical lymph node metastasis (LNM) can be identified in 40--90% of cases at the time of the first surgery ([@b3-ol-0-0-6694]). The most typical LNM site is the central neck compartment (level VI). LNM has been confirmed to be an independent risk factor for regional recurrence ([@b4-ol-0-0-6694]--[@b6-ol-0-0-6694]) and decreased survival ([@b7-ol-0-0-6694]--[@b9-ol-0-0-6694]). The American Joint Committee on Cancer advocates the surgical removal of suspected lymph nodes detected by preoperative ultrasonography ([@b10-ol-0-0-6694]). However, a routine central neck lymph node dissection (LND) in patients with subclinical nodal disease (cN0) is controversial. On one hand, LNM occurs in 60% of patients with PTC on average ([@b11-ol-0-0-6694]) and metastasis has been reported in ≤50% of dissected lymph nodes in cN0 patients ([@b12-ol-0-0-6694]). Prophylactic LND can remove subclinical metastatic lymph nodes, thus avoiding potential recurrence in addition to aiding in disease staging for radioiodine therapy ([@b4-ol-0-0-6694],[@b13-ol-0-0-6694]). On the other hand, previous studies have reported that prophylactic LND in cN0 patients increases the rate of recurrent laryngeal nerve injury and hypoparathyroidism, which would be disadvantageous for patients with PTC ([@b14-ol-0-0-6694],[@b15-ol-0-0-6694]).

The T1799A nucleotide transversion in the B-Raf proto-oncogene (BRAF) gene (NM_004333) causes a V600E amino acid substitution and leads to constitutive activation of the mitogen-activated protein kinase signaling pathway ([@b16-ol-0-0-6694]). Previous studies have demonstrated that BRAF^V600E^ is the most frequent genetic change in PTC, with prevalence ranging from 27 to 83% ([@b17-ol-0-0-6694],[@b18-ol-0-0-6694]). The association between BRAF^V600E^ and central LNM has been widely investigated. The majority of studies support that BRAF^V600E^ is associated with the presence of LNM and the probability of recurrence ([@b18-ol-0-0-6694]--[@b20-ol-0-0-6694]). Certain studies considered that patients with the BRAF^V600E^ mutation should receive LND in the central compartment ([@b18-ol-0-0-6694],[@b21-ol-0-0-6694],[@b22-ol-0-0-6694]). However, other studies reported that the correlation between BRAF^V600E^ and tumor aggressiveness, involving LNM, was not evident ([@b23-ol-0-0-6694],[@b24-ol-0-0-6694]). Thus, this divergence in the association between BRAF^V600E^ and more aggressive clinicopathological characteristics deserves further in-depth investigation.

To date, to the best of our knowledge, just one previous study has investigated the clinical significance of BRAF^V600E^ for central LNM based on preoperative central lymph node status and various histological subtypes of PTC ([@b25-ol-0-0-6694]). Therefore, the present study was designed to separately assess the clinical significance of BRAF^V600E^ in patients with cN0 and cN1 PTC with different histological subtypes.

Methods and patients
====================

### Patients

A total of 793 patients accepted thyroidectomy in Department of Surgical Oncology of the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) between January 2007 and April 2011. These patients were diagnosed with PTC during the final pathological examination. All patients came from the eastern coastal regions in China. Eligibility criteria were as follows: Patients\' acceptance of total thyroidectomy plus central LND, absence of a history of neck surgery or radiotherapy on the thyroid, and absence of other types of head and neck cancer. A total of 397 patients were excluded from the present study as they only underwent thyroidectomy, 93 were disqualified for having a previous history of neck surgery or radiotherapy on the thyroid gland, and another 16 were omitted for their history of other types of head and neck cancer. Finally, 287 patients with PTC with total thyroidectomy plus central LND were enrolled.

Clinicopathological data included patients\' age at diagnosis, sex, tumor size, Hashimoto\'s thyroiditis, multifocality, extrathyroidal extension, thyroid capsular invasion, central LNM and tumor histological subtype. If \>1 malignant nodule existed in the thyroid gland, the largest nodule was analyzed. cN0 patients were those patients without preoperative clinical or ultrasonic evidence of central LNM and without suspicious lymph nodes identified during surgery; otherwise, the patients were categorized as cN1 patients. The Institutional Review Board of Wenzhou Medical University approved the present study, and written informed consent was obtained from all patients included.

### DNA extraction and BRAF mutation analysis

Genomic DNA was isolated from formalin-fixed paraffin-embedded 7-µm tissue sections using a QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s protocol. BRAF exon 15 was amplified via polymerase chain reaction (PCR) with the following primers: Forward, 5′-TCATAATGCTTGCTCTGATAGGA-3′ and reverse, 5′-GGCCAAAAATTTAATCAGTGGA-3′. A 3-µl sample of the DNA template was added into a 50 µl (total volume) reaction containing 25 µl 2X PCR Reagent (containing 0.1 U/µl Taq polymerase, 500 µM dNTP each, 20 mM Tris-HCl, 100 mM KCl, 3 mM MgCl~2~), 2 µl of each primer, and 18 µl dH~2~O (all Tiangen Biotech Co., Ltd., Beijing, China). The PCR conditions were 94°C for 3 min, followed by 35 cycles of 94°C for 30 sec, 55°C for 30 sec, 72°C for 1 min and 72°C for 5 min. The quality of the PCR products was confirmed by 2% agarose gel electrophoresis. Each test was repeated in triplicate, with dH~2~O used as the negative control. The PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, USA) on an ABI PRISM 3730XL DNA Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) to identify the mutation.

### Statistical analysis

Statistical analysis was performed using IBM SPSS software (version 19.0; IBM Corp., Armonk, NY, USA). A univariate analysis was conducted to reveal the risk factors associated with central LNM in different histological subtypes of PTC. Factors that demonstrated significant differences were further tested through multivariate analysis. Data were described as the number of cases for categorical variables. Confrontations between different groups were performed using a χ^2^ test. When the sample size was \<40 or with a theoretical frequency of \<1, Fisher\'s exact test was used instead. For continuous variables, data were described as the mean ± standard deviation. A multivariate analysis was performed using binary logistic regression. The results were presented as odds ratios (ORs) with 95% confidence intervals (CIs). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient clinicopathological characteristics

A total of 287 patients with PTC were included in the present study. Patient ages ranged between 9 and 77 years, with a mean of 43.82±11.96 years. The female-to-male ratio was 4.86 (49 males vs. 238 females). A total of 1,985 lymph nodes from the central compartment were dissected, among which 837 were identified as cancer metastases by pathologists (2.9 metastatic lymph nodes to 6.9 total lymph nodes dissected from each patient on average). Central LNM was identified in 189 patients (65.85%), and underlying Hashimoto\'s thyroiditis was identified in 112 patients (39.02%). Other characteristics such as multifocality, extrathyroidal extension and thyroid capsular invasion were identified in 85 (29.62%), 87 (30.31%) and 109 (37.98%) patients, respectively. Among the patients, 172 (59.93%) were patients with cN0 PTC, whereas the other 115 (40.07%) were patients with cN1 PTC. According to the histological subtype classification, 177 (61.67%) and 94 (32.75%) patients were diagnosed with CVPTC and FVPTC, respectively. The remaining 16 patients (5.57%) were grouped under AVPTC, which included tall cell, diffuse sclerosing and poorly differentiated PTC subtypes.

### Distribution of central LNM and BRAF^V600E^

Among the patients with cN0 PTC, LNM could be identified in 63 patients (58.88%) in the CVPTC group, 21 patients (35.00%) in the FVPTC group and 3 patients (60.00%) in the AVPTC group; the proportion in the cN1 group was 64 (91.43%), 29 (85.29%) and 9 (81.82%) patients in the CVPTC, FVPTC and AVPTC groups, respectively ([Fig. 1A and B](#f1-ol-0-0-6694){ref-type="fig"}). Similarly, among all patients with cN0 PTC, BRAF^V600E^ was detected in 68 patients (63.55%) in the CVPTC group, 29 patients (48.33%) in the FVPTC group and all 5 patients (100.00%) in the AVPTC group; the proportion in the cN1 group was 46 (65.71%), 15 (44.12%) and 8 (72.72%) patients in the CVPTC, FVPTC, and AVPTC groups, respectively ([Fig. 1C and D](#f1-ol-0-0-6694){ref-type="fig"}).

### Univariate and multivariate analyses in all patients with PTC

Among all patients with PTC ([Table I](#tI-ol-0-0-6694){ref-type="table"}), BRAF^V600E^ was associated with a higher rate of central LNM (73.10 vs. 55.17%; P=0.002). Underlying Hashimoto\'s thyroiditis was negatively correlated with central LNM (58.93 vs. 70.29%, P=0.048). In addition, central LNM occurred more frequently in patients with larger tumor size, extrathyroidal extension, thyroid capsular invasion and BRAF^V600E^ (82.56 vs. 58.71%, P\<0.001; 78.16 vs. 60.50%, P=0.004; and 76.15 vs. 56.08%, P=0.004, respectively). These significantly different factors were then analyzed by multivariate logistic regression. The results demonstrated that BRAF^V600E^ was independently associated with central LNM with an OR value of 1.708 (95% CI, 1.004--2.094; P=0.048). In addition, large tumor size was an independent risk factor for central LNM with an OR value of 2.621 (95% CI, 1.365--5.034; P=0.004).

Among all patients with cN1 PTC ([Table II](#tII-ol-0-0-6694){ref-type="table"}), BRAF^V600E^ was the only factor correlated with central LNM (94.20 vs. 80.43%; P=0.022). Only 13 patients did not exhibit central LNM in this cohort. Central LNM had a higher prevalence in patients with large tumor size (95.24 vs. 84.93%; P=0.169), extrathyroidal extension (95.56 vs. 84.29%; P=0.063) and thyroid capsular invasion (93.62 vs. 85.29%, P=0.166); however, these results were not statistically significant.

Among all patients with cN0 PTC ([Table III](#tIII-ol-0-0-6694){ref-type="table"}), central LNM was identified in 58.82% of BRAF^V600E^-positive patients compared with 38.57% of BRAF^V600E^-negative patients (P=0.009). Additionally, a higher rate of central LNM was revealed in patients with larger tumor size and thyroid capsular invasion (70.45 vs. 43.75%, P=0.002; and 62.90 vs. 43.64%, P=0.015, respectively). Underlying Hashimoto\'s thyroiditis was negatively correlated with central LNM (41.43 vs. 56.86%, P=0.047). These four significantly different factors were further examined using multivariate analysis. Large tumor size was the only independent risk factor for central LNM with an OR value of 2.633 (95% CI, 1.189--5.832; P=0.017). However, BRAF^V600E^ was not associated with central LNM in the multivariate analysis (P=0.059), which was inconsistent with the overall result for the patients with PTC in the present study.

### Univariate and multivariate analyses of patients with CVPTC

A total of 177 patients were diagnosed with CVPTC in the present study; 70 (39.55%) of these patients were cN1, and 107 (60.45%) were cN0. Tumor size \>2 cm (87.27 vs. 64.75%; P=0.002), underlying Hashimoto\'s thyroiditis (60.81 vs. 79.61%; P=0.006), extrathyroidal extension (86.00 vs. 66.14%; P=0008), thyroid capsular invasion (87.93 vs. 63.87%; P=0.001) and BRAF^V600E^ (79.82 vs. 57.14%; P=0.001) were all correlated with central LNM in the univariate analysis ([Table IV](#tIV-ol-0-0-6694){ref-type="table"}). The aforementioned factors were then included in the multivariate analysis. Tumor size \>2 cm (OR, 2.656; 95% CI, 1.049--6.724; P=0.039), underlying Hashimoto\'s thyroiditis (OR, 0.410; 95% CI, 0.200--0.841; P=0.015) and thyroid capsular invasion (OR, 2.941; 95% CI, 1.054--8.202; P=0.039) were all independently associated with central LNM. Notably, BRAF^V600E^ was independently associated with central LNM in patients with CVPTC (OR, 2.243; 95% CI, 1.080--4.658; P=0.030).

Similar analyses were performed on 70 patients with cN1 CVPTC ([Table V](#tV-ol-0-0-6694){ref-type="table"}). The results revealed that only thyroid capsular invasion was associated with central LNM (100.00 vs. 85.37%; P=0.038). Other factors, including BRAF^V600E^ (95.65 vs. 83.33%, P=0.171) were not statistically different between the central LNM-positive and -negative groups.

Among the 107 patients with cN0 CVPTC ([Table VI](#tVI-ol-0-0-6694){ref-type="table"}), central LNM was correlated with BRAF^V600E^ (69.12 vs. 41.03%; P=0.004), tumor size \>2 cm (75.00 vs. 53.16%; P=0.044) and thyroid capsular invasion (75.86 vs. 52.56%; P=0.029). Underlying Hashimoto\'s thyroiditis was negatively associated with central LNM (46.94 vs. 68.97%, P=0.021). When these factors were included in the multivariate analysis, BRAF^V600E^ was identified to be an independent risk factor for central LNM (P=0.032), with an OR value of 2.586 (95% CI, 1.087--6.151), and underlying Hashimoto\'s thyroiditis was an independent negative factor in this cohort (P=0.042), with an OR value of 0.411 (95% CI, 0.174--0.970).

### Univariate and multivariate analyses of patients with FVPTC

The aforementioned factors were analyzed in a total of 94 patients with FVPTC ([Table VII](#tVII-ol-0-0-6694){ref-type="table"}), which comprised 34 patients with cN1 FVPTC ([Table VIII](#tVIII-ol-0-0-6694){ref-type="table"}) and 60 patients with cN0 FVPTC ([Table IX](#tIX-ol-0-0-6694){ref-type="table"}). However, central LNM was only associated with thyroid capsular invasion in the patients with cN0 FVPTC (P=0.015). None of the other factors were associated with central LNM regardless of preoperative lymph node status. Central LNM rate was not significantly different between BRAF^V600E^-positive and -negative patients (54.55 vs. 52.00%, P=0.805 in all patients with FVPTC; 93.33 vs. 78.95%, P=0.355 in cN1 patients; 34.48 vs. 35.48%, P=0.935 in cN0 patients).

### Univariate and multivariate analyses of patients with AVPTC

Given that the patient number in this cohort was limited to 12 and 4 patients in the central LNM-positive and -negative groups, respectively, the risk factors were analyzed in all patients with AVPTC together ([Table X](#tX-ol-0-0-6694){ref-type="table"}) instead of analyzing them separately by preoperative lymph node status. Central LNM rate demonstrated a higher trend in patients with extrathyroidal extension, thyroid capsular invasion (80.00 vs. 72.73% for the two factors) and BRAF^V600E^ (76.92 vs. 66.67%). However, none of these factors were significantly different.

Discussion
==========

Risk factors associated with central LNM in patients with PTC have been widely studied; tumor size, extrathyroidal extension, thyroid capsular invasion, underlying Hashimoto\'s thyroiditis and BRAF^V600E^ have been reported to be associated with LNM ([@b26-ol-0-0-6694]--[@b28-ol-0-0-6694]). BRAF^V600E^ has been demonstrated to be a good risk factor for cervical LNM and was significantly correlated with recurrence ([@b18-ol-0-0-6694],[@b19-ol-0-0-6694]). Nevertheless, certain studies have revealed no correlation between BRAF^V600E^ and cervical LNM ([@b29-ol-0-0-6694],[@b30-ol-0-0-6694]).

PTC is composed of several distinct histological subtypes, including CVPTC, FVPTC and AVPTC; AVPTC includes tall cell PTC, diffuse sclerosing PTC and poorly differentiated PTC, which all exhibit more aggressive biological behavior ([@b19-ol-0-0-6694]). In the present study, 287 patients with PTC, comprising 177 patients with CVPTC, 94 patients with FVPTC and 16 patients with AVPTC, were analyzed. Multivariate regression analysis revealed that BRAF^V600E^ was independently associated with central LNM in the overall PTC group, which is in accordance with previous reports ([@b18-ol-0-0-6694],[@b19-ol-0-0-6694]). However, similar results cannot be drawn from FVPTC or AVPTC, as the BRAF mutation rate was not significantly different between these two PTC subtypes. Importantly, BRAF^V600E^ in CVPTC, which is the most common subtype, was a potent independent indicator for central LNM in addition to the overall PTC group. FVPTC presented some similarities with follicular thyroid carcinoma, and BRAF^V600E^ exhibited a relatively low prevalence in this PTC subtype ([@b31-ol-0-0-6694]). The results from the present study are in agreement with studies by Walts *et al* ([@b32-ol-0-0-6694]) and Li *et al* ([@b33-ol-0-0-6694]), which stated that BRAF^V600E^ was not associated with LNM in FVPTC. The difference in BRAF^V600E^ mutation rate was not significant in patients with AVPTC who had a high incidence of BRAF^V600E^ between LNM-positive (83.33%) and -negative (75.00%) groups. The significance of the association between BRAF^V600E^ and LNM in AVPTC may be concealed by such a high rate of BRAF^V600E^. As a consequence, BRAF mutation may perform differently in diverse subtypes. Thus, the divergence in the association between BRAF mutation and central LNM in previous studies may be a result of the different histological subtypes of PTC.

Although previous studies have demonstrated that cervical LNM is associated with local recurrence and even disease-specific survival in patients with PTC ([@b7-ol-0-0-6694],[@b34-ol-0-0-6694]), prophylactic central LND in patients with cN0 PTC remains controversial in thyroid cancer surgery. In the systematic review by Mulla and Schulte ([@b35-ol-0-0-6694]), cancerous lymph nodes were detected in 46.15% of 1,946 patients with cN0 PTC. Therefore, Mulla and Schulte ([@b35-ol-0-0-6694]) advocated for prophylactic central LND to be performed on patients with PTC. By contrast, a previous study by Conzo *et al* ([@b15-ol-0-0-6694]) of 752 patients with cN0 PTC revealed a greater rate of surgical complications, including permanent hypoparathyroidism (3.6 vs. 1%; P=0.018) and temporary unilateral vocal cord palsy (3.5% vs. 1.2; P=0.039). Therefore, Conzo *et al* ([@b15-ol-0-0-6694]) stated that prophylactic central LND in patients with cN0 PTC should be used selectively.

To improve the pertinence of prophylactic central LND in patients with cN0 PTC and to avoid potential surgical morbidity, the data was further analyzed based on preoperative central lymph node status; the analyses were performed separately for patients with cN0 and cN1 PTC. Univariate analysis of all patients with PTC revealed that BRAF^V600E^ was associated with central LNM in the 115 patients with cN1 PTC and the 172 patients with cN0 PTC. However, in the multivariate regression analysis, BRAF^V600E^ was significant in neither patients with cN0 PTC nor in patients with cN1 PTC, suggesting that the effect of BRAF^V600E^ as an indicator for performing prophylactic central LND was limited in this cohort of patients.

When the patients were subdivided into variant histological subtypes, in the univariate analysis BRAF^V600E^ was a potent indicator for central LNM in patients with CVPTC, in addition to patients with cN0 CVPTC, but not for cN1 patients of this variant. In the multivariate regression, BRAF^V600E^ was independently correlated with central LNM in all patients with CVPTC and patients with cN0 CVPTC, but not in cN1 patients of this subtype.

The aforementioned research demonstrating a correlation between BRAF^V600E^ and central LNM ([@b26-ol-0-0-6694]--[@b28-ol-0-0-6694]) may not be representative of all patients with PTC. As demonstrated in the present study, BRAF^V600E^ was independently associated with central LNM in overall patients with PTC, but when subdivided by histological variant, BRAF^V600E^ was only significantly associated with the CVPTC subtype. In addition, when categorized by preoperative central lymph node status, BRAF^V600E^ was only independently associated with central LNM in patients with cN0 CVPTC instead of in all patients with cN0 PTC. For patients with cN1 CVPTC, suspected LNM was already detected on preoperative ultrasonography and surgical removal of regional lymph nodes was typically recommended, thus the clinical significance of BRAF^V600E^ or other clinicopathological features was limited. As a consequence, BRAF^V600E^ was only associated with central LNM in a selected cohort of patients instead of all patients with PTC.

Other clinicopathological factors have been associated with central LNM. Tumor size has been demonstrated to be an important risk factor for central LNM in numerous studies ([@b28-ol-0-0-6694],[@b33-ol-0-0-6694]). In the present study, tumor size was significantly different between central LNM-positive or -negative patients in overall patients with PTC and patients with CVPTC, in addition to in the univariate analysis. Furthermore, tumor size was an independent factor in the multivariate analysis. Upon further investigation using surgical approaches, tumor size was revealed to be associated with central LNM in overall patients with cN0 PTC and in patients with cN0 CVPTC, and was the only independent risk factor associated with central LNM in overall patients with cN0 PTC. Additionally, no significant differences were identified between patients with FVPTC and patients with AVPTC with or without LNM. Thyroid capsular invasion is another widely investigated risk factor for central LNM ([@b26-ol-0-0-6694],[@b27-ol-0-0-6694]). The data from the present study demonstrated that thyroid capsular invasion was associated with central LNM in a number of comparison groups, as revealed by the univariate analysis results. Thyroid capsular invasion was the only significantly different factor for central LNM in patients with cN1 CVPTC.

Previous studies have demonstrated that underlying Hashimoto\'s thyroiditis has a protective effect for patients with PTC, and that it is associated with smaller tumor size, fewer LNM and improved prognosis ([@b36-ol-0-0-6694],[@b37-ol-0-0-6694]). The data from the present study demonstrated that underlying Hashimoto\'s thyroiditis was negatively correlated with central LNM in overall patients with PTC and patients with CVPTC. When further analyzed, the difference was only significant in overall patients with cN0 PTC and in patients with cN0 CVPTC. Underlying Hashimoto\'s thyroiditis serves as an independent factor only in patients with cN0 CVPTC. Considering that a great fraction of patients with cN1 who received therapeutic LND had central LNM, the suspected regional lymph nodes should be routinely removed. Aggressive features, including larger tumor size, multifocality, extrathyroidal extension, thyroid capsular invasion and BRAF^V600E^ became less important under such a high ratio of central LNM.

The present study has certain limitations. The sample size was not big enough, particularly for patients with s; only 16 patients with AVPTC in total were analyzed in the present study, which may affect the statistics. Additionally, on account of insufficient numbers of patients, the analyses of patients with cN0 and cN1 AVPTC were not performed separately. The association between BRAF^V600E^ and other risk factors with long-term follow-up data in different subgroups require further investigation in order to unveil their prognostic function in different histological subtypes and preoperative central lymph node statuses.

In conclusion, the clinical significance of BRAF^V600E^ for central LNM depends not only on PTC histological subtype, but also on preoperative central lymph node status, with the greatest significance in patients with cN0 CVPTC instead of all patients with PTC. Furthermore, BRAF^V600E^ alone may not be able to accurately indicate the central lymph node status. Hence, other associated factors should also be recognized.

The present study was supported by the National High Technology Research and Development Program of China (863 Program) (grant no. 2012AA02A210) and the Zhejiang Provincial Natural Science Foundation of Zhejiang (China) (grant no. Y13H16011).
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###### 

Univariate and multivariate analyses of associations between central LNM and clinicopathological characteristics in overall patients with PTC.

                                              Univariate analyses                                               
  ------------------------------------- ----- --------------------- ------------ ------- ---------------------- -------
  Total number                          287   189                   98                                          
  Age at diagnosis, years                                                                                       
    ≥45                                 129   87 (67.44)            42 (32.56)   0.608                          
    \<45                                158   102 (64.56)           56 (35.44)                                  
  Sex                                                                                                           
    Female                              238   155 (65.13)           83 (34.83)   0.567                          
    Male                                49    34 (69.39)            15 (30.61)                                  
  Pathological tumor size, cm                                                                                   
    \>2                                 86    71 (82.56)            15 (17.44)   0.000   2.621(1.365--5.034)    0.004
  ≤2                                    201   118 (58.71)           83 (41.29)                                  
  Underlying Hashimoto\'s thyroiditis                                                                           
    Present                             112   66 (58.93)            46 (41.07)   0.048   0.652 (0.396--1.099)   0.108
    Absent                              175   123 (70.29)           52 (29.71)                                  
  Multifocality                                                                                                 
    Present                             85    63 (74.12)            22 (25.88)   0.055                          
  Absent                                202   126 (62.38)           76 (37.62)                                  
  Extrathyroidal extension                                                                                      
    Present                             87    68 (78.16)            19 (21.84)   0.004   1.391 (0.702--2.757)   0.344
    Absent                              200   121 (60.50)           79 (39.50)                                  
  Thyroid capsular invasion                                                                                     
    Present                             109   83 (76.15)            26 (23.85)   0.004   1.477 (0.794--2.747)   0.218
    Absent                              178   106 (56.08)           72 (73.47)                                  
  BRAF mutation                                                                                                 
    Positive                            171   125 (73.10)           46 (26.90)   0.002   1.708 (1.004--2.094)   0.048
    Negative                            116   64 (55.17)            52 (44.83)                                  

LNM, lymph node metastasis; PTC, papillary thyroid cancer; OR, odds ratio; CI, confidence interval; BRAF, B-Raf proto-oncogene.

###### 

Univariate analyses of associations between central LNM and clinicopathological features in overall patients with cN1 PTC.

  Clinicopathological characteristic    Total, n   Central LNM(+), n (%)   Central LNM(−), n (%)   P-value
  ------------------------------------- ---------- ----------------------- ----------------------- ----------------------------------------------------
  Total number                          115        102                     13                      
  Age at diagnosis, years                                                                          
    ≥45                                 60         53 (88.33)              7 (11.67)               0.898
    \<45                                55         49 (89.09)              6 (10.90)               
  Sex                                                                                              
    Female                              90         78 (86.67)              12 (13.33)              0.344^[a](#tfn2-ol-0-0-6694){ref-type="table-fn"}^
    Male                                25         24 (96.00)              1 (4.00)                
  Pathological tumor size, cm                                                                      
    \>2                                 42         40 (95.24)              2 (4.76)                0.169^[a](#tfn2-ol-0-0-6694){ref-type="table-fn"}^
    ≤2                                  73         62 (84.93)              11 (15.07)              
  Underlying Hashimoto\'s thyroiditis                                                              
    Present                             42         37 (88.10)              5 (11.90)               1.000^[a](#tfn2-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              73         65 (89.04)              8 (10.96)               
  Multifocality                                                                                    
    Present                             44         38 (86.36)              6 (13.64)               0.750^[a](#tfn2-ol-0-0-6694){ref-type="table-fn"}^
  Absent                                71         64 (90.14)              7 (9.86)                
  Extrathyroidal extension                                                                         
    Present                             45         43 (95.56)              2 (4.44)                0.063
    Absent                              70         59 (84.29)              11 (15.71)              
  Thyroid capsular invasion                                                                        
    Present                             47         44 (93.62)              3 (6.38)                0.166
    Absent                              68         58 (85.29)              10 (14.71)              
  BRAF mutation                                                                                    
    Positive                            69         65 (94.20)              4 (5.80)                0.022
    Negative                            46         37 (80.43)              9 (19.57)               

P-value using χ^2^ test continuity correction. LNM, lymph node metastasis; PTC, papillary thyroid cancer; BRAF, B-Raf proto-oncogene; cN1, all other patients (not cN0).

###### 

Univariate and multivariate analyses of associations between central LNM and clinicopathological features in overall patients with cN0 PTC.

                                              Univariate analyses                                               
  ------------------------------------- ----- --------------------- ------------ ------- ---------------------- -------
  Total number                          172   87                    85                                          
  Age at diagnosis, years                                                                                       
    ≥45                                 69    34 (49.28)            35 (50.72)   0.779                          
    \<45                                103   53 (51.46)            50 (48.54)                                  
  Sex                                                                                                           
    Female                              148   77 (52.03)            71 (47.97)   0.346                          
    Male                                24    10 (41.67)            14 (58.33)                                  
  Pathological tumor size, cm                                                                                   
    \>2                                 44    31 (70.45)            13 (29.55)   0.002   2.633 (1.189--5.832)   0.017
    ≤2                                  128   56 (43.75)            72 (56.25)                                  
  Underlying Hashimoto\'s thyroiditis                                                                           
    Present                             70    29 (41.43)            41 (58.57)   0.047   0.559 (0.288--1.086)   0.086
    Absent                              102   58 (56.86)            44 (43.14)                                  
  Multifocality                                                                                                 
    Present                             41    25 (60.98)            16 (39.02)   0.127                          
    Absent                              131   62 (47.33)            69 (52.67)                                  
  Extrathyroidal extension                                                                                      
    Present                             42    25 (59.52)            17 (40.48)   0.182                          
    Absent                              130   62 (47.69)            68 (52.31)                                  
  Thyroid capsular invasion                                                                                     
    Present                             62    39 (62.90)            23 (37.10)   0.015   1.692 (0.850--3.370)   0.134
    Absent                              110   48 (43.64)            62 (56.36)                                  
  BRAF mutation                                                                                                 
    Positive                            102   60 (58.82)            42 (41.18)   0.009   1.882 (0.976--3.629)   0.059
    Negative                            70    27 (38.57)            43 (61.43)                                  

LNM, lymph node metastasis; PTC, papillary thyroid cancer; OR, odds ratio; CI, confidence interval; BRAF, B-Raf proto-oncogene; cN0, subclinical nodal disease.

###### 

Univariate and multivariate analyses of associations between central LNM and clinicopathological features in patients with CVPTC.

                                              Univariate analyses                                                       
  ------------------------------------- ----- --------------------- ------------ ------- ---------------------- ------- --
  Total number                          177   127                   50                                                  
  Age at diagnosis, years                                                                                               
    ≥45                                 75    56 (74.67)            19 (25.33)   0.460                                  
    \<45                                102   71 (69.61)            31 (3.39)                                           
  Sex                                                                                                                   
    Female                              148   103 (69.59)           45 (30.41)   0.150                                  
    Male                                29    24 (82.76)            5 (17.24)                                           
  Pathological tumor size, cm                                                                                           
    \>2                                 55    48 (87.27)            7 (12.73)    0.002   2.656 (1.049--6.724)   0.039   
    ≤2                                  122   79 (64.75)            43 (35.25)                                          
  Underlying Hashimoto\'s thyroiditis                                                                                   
    Present                             74    45 (60.81)            29 (39.19)   0.006   0.410 (0.200--0.841)   0.015   
    Absent                              103   82 (79.61)            21 (20.39)                                          
  Multifocality                                                                                                         
    Present                             50    41 (82.00)            9 (18.00)    0.057                                  
    Absent                              127   86 (67.72)            41 (32.28)                                          
  Extrathyroidal extension                                                                                              
    Present                             50    43 (86.00)            7 (14.00)    0.008   1.358 (0.470--3.926)   0.572   
    Absent                              127   84 (66.14)            43 (33.86)                                          
  Thyroid capsular invasion                                                                                             
    Present                             58    51 (87.93)            7 (12.07)    0.001   2.941 (1.054--8.202)   0.039   
    Absent                              119   76 (63.87)            43 (36.13)                                          
  BRAF mutation                                                                                                         
    Positive                            114   91 (79.82)            23 (20.18)   0.001   2.243 (1.080--4.658)   0.030   
    Negative                            63    36 (57.14)            27 (42.86)                                          

LNM, lymph node metastasis; CVPTC, classical variant papillary thyroid cancer; OR, odds ratio; CI, confidence interval; BRAF, B-Raf proto-oncogene.

###### 

Univariate analyses of associations between central LNM and clinicopathological features in patients with cN1 CVPTC.

  Clinicopathological characteristic    Total, n   Central LNM (+), n (%)   Central LNM (−), n (%)   P-value
  ------------------------------------- ---------- ------------------------ ------------------------ ----------------------------------------------------
  Total number                          70         64                       6                        
  Age at diagnosis, years                                                                            
    ≥45                                 37         35 (94.59)               2 (5.41)                 0.411^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    \<45                                33         29 (87.88)               4 (12.12)                
  Sex                                                                                                
    Female                              53         48 (90.67)               5 (9.43)                 1.000^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    Male                                17         16 (94.12)               1 (5.88)                 
  Pathological tumor size, cm                                                                        
    \>2                                 27         27 (100.00)              0 (0.00)                 0.075^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    ≤2                                  43         37 (86.05)               6 (13.95)                
  Underlying Hashimoto\'s thyroiditis                                                                
    Present                             25         22 (88.00)               3 (12.00)                0.659^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              45         42 (93.33)               3 (6.67)                 
  Multifocality                                                                                      
    Present                             26         24 (92.31)               2 (7.69)                 1.000^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              44         40 (90.91)               4 (9.09)                 
  Extrathyroidal extension                                                                           
    Present                             27         27 (100.00)              0 (0.00)                 0.075^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              43         37 (86.05)               6 (13.95)                
  Thyroid capsular invasion                                                                          
    Present                             29         29 (100.00)              0 (0.00)                 0.038^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              41         35 (85.37)               6 (14.63)                
  BRAF mutation                                                                                      
    Positive                            46         44 (95.65)               2 (4.35)                 0.171^[a](#tfn5-ol-0-0-6694){ref-type="table-fn"}^
    Negative                            24         20 (83.33)               4 (16.67)                

P-value using Fisher\'s exact test. LNM, lymph node metastasis; CVPTC, classical variant papillary thyroid cancer; BRAF, B-Raf proto-oncogene; cN1, all other patients (not cN0).

###### 

Univariate and multivariate analyses of associations between central LNM and clinicopathological features in patients with cN0 CVPTC.

                                              Univariate analyses                                                                                            
  ------------------------------------- ----- --------------------- ------------ ---------------------------------------------------- ---------------------- -------
  Total number                          107   63                    44                                                                                       
  Age at diagnosis, years                                                                                                                                    
    ≥45                                 38    21 (55.26)            17 (44.74)   0.573                                                                       
    \<45                                69    42 (60.87)            27 (39.13)                                                                               
  Sex                                                                                                                                                        
    Female                              95    55 (57.89)            40 (42.11)   0.787^[a](#tfn6-ol-0-0-6694){ref-type="table-fn"}^                          
    Male                                12    8 (66.67)             4 (33.33)                                                                                
  Pathological tumor size, cm                                                                                                                                
    \>2                                 28    21 (75.00)            7 (25.00)    0.044                                                2.261 (0.790--6.468)   0.128
    ≤2                                  79    42 (53.16)            37 (46.84)                                                                               
  Underlying Hashimoto\'s thyroiditis                                                                                                                        
    Present                             49    23 (46.94)            26 (53.06)   0.021                                                0.411 (0.174--0.970)   0.042
    Absent                              58    40 (68.97)            18 (31.03)                                                                               
  Multifocality                                                                                                                                              
    Present                             24    17 (70.83)            7 (29.17)    0.177                                                                       
    Absent                              83    46 (55.42)            37 (44.58)                                                                               
  Extrathyroidal extension                                                                                                                                   
    Present                             23    16 (69.57)            7 (30.43)    0.240                                                                       
    Absent                              84    47 (55.95)            37 (44.05)                                                                               
  Thyroid capsular invasion                                                                                                                                  
    Present                             29    22 (75.86)            7 (24.14)    0.029                                                2.512 (0.885--7.135)   0.084
    Absent                              78    41 (52.56)            37 (47.44)                                                                               
  BRAF mutation                                                                                                                                              
    Positive                            68    47 (69.12)            21 (30.88)   0.004                                                2.586 (1.087--6.151)   0.032
    Negative                            39    16 (41.03)            23 (58.97)                                                                               

P-value using χ^2^ test continuity correction. LNM, lymph node metastasis; CVPTC, classical variant papillary thyroid cancer; OR, odds ratio; CI, confidence interval; BRAF, B-Raf proto-oncogene; cN0, subclinical nodal disease.

###### 

Univariate analyses of associations between central LNM and clinicopathological characteristics in patients with FVPTC.

  Clinicopathological characteristic    Total, n   Central LNM (+), n (%)   Central LNM (−), n (%)   P-value
  ------------------------------------- ---------- ------------------------ ------------------------ ---------
  Total number                          94         50                       44                       
  Age at diagnosis, years                                                                            
    ≥45                                 49         27 (55.10)               22 (44.90)               
    \<45                                45         23 (51.11)               22 (48.89)               0.689
  Sex                                                                                                
    Female                              78         42 (53.85)               36 (46.15)               0.779
    Male                                16         8 (50.00)                8 (50.18)                
  Pathological tumor size, cm                                                                        
    \>2                                 24         16 (66.67)               8 (33.33)                0.125
    ≤2                                  70         34 (48.57)               36 (51.43)               
  Underlying Hashimoto\'s thyroiditis                                                                
    Present                             31         16 (51.61)               15 (48.39)               0.83
    Absent                              63         34 (53.97)               29 (46.03)               
  Multifocality                                                                                      
    Present                             28         17 (60.71)               11 (39.29)               0.341
    Absent                              66         33 (50.00)               33 (50.00)               
  Extrathyroidal extension                                                                           
    Present                             32         21 (65.63)               11 (34.37)               0.083
    Absent                              62         29 (46.77)               33 (53.23)               
  Thyroid capsular invasion                                                                          
    Present                             46         28 (60.87)               18 (39.13)               0.144
    Absent                              48         22 (45.83)               26 (54.17)               
  BRAF mutation                                                                                      
    Positive                            44         24 (54.55)               20 (45.45)               0.805
    Negative                            50         26 (52.00)               24 (48.00)               

LNM, lymph node metastasis; FVPTC, follicular variant papillary thyroid cancer; BRAF, B-Raf proto-oncogene.

###### 

Univariate analyses of associations between central LNM and clinicopathological characteristics in patients with cN1 FVPTC.

  Clinicopathological characteristic    Total, n   Central LNM (+), n (%)   Central LNM (−), n (%)   P-value
  ------------------------------------- ---------- ------------------------ ------------------------ ----------------------------------------------------
  Total number                          34         29                       5                        
  Age at diagnosis, years                                                                            
    ≥45                                 20         16 (80.00)               4 (20.00)                
    \<45                                14         13 (92.86)               1 (7.14)                 0.298^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
  Sex                                                                                                
    Female                              28         23 (82.14)               5 (17.86)                0.559^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    Male                                6          6 (100.00)               0 (0.00)                 
  Pathologic tumor size, cm                                                                          
    ≤2                                  24         21 (87.50)               3 (12.50)                0.618^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    \>2                                 10         8 (80.00)                2 (20.00)                
  Underlying Hashimoto\'s thyroiditis                                                                
    Present                             12         11 (91.67)               1 (8.33)                 0.635^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              22         18 (81.82)               4 (18.18)                
  Multifocality                                                                                      
    Present                             12         10 (83.33)               2 (16.67)                1.000^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              22         19 (86.36)               3 (13.64)                
  Extrathyroidal extension                                                                           
    Present                             15         13 (86.67)               2 (13.33)                1.000^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              19         16 (84.21)               3 (15.79)                
  Thyroid capsular invasion                                                                          
    Present                             16         13 (81.25)               3 (18.75)                1.000^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              18         16 (88.89)               2 (11.11)                
  BRAF mutation                                                                                      
    Positive                            15         14 (93.33)               1 (6.67)                 0.355^[a](#tfn8-ol-0-0-6694){ref-type="table-fn"}^
    Negative                            19         15 (78.95)               4 (21.05)                

P-value using Fisher\'s exact test. LNM, lymph node metastasis; FVPTC, follicular variant papillary thyroid cancer. BRAF, B-Raf proto-oncogene; cN1, all other patients (not cN0).

###### 

Univariate analyses of associations between of central LNM and clinicopathological features in patients with cN0 FVPTC.

  Clinicopathological characteristic    Total, n   Central LNM (+), n (%)   Central LNM (−), n (%)   P-value
  ------------------------------------- ---------- ------------------------ ------------------------ ----------------------------------------------------
  Total number                          60         21                       39                       
  Age at diagnosis, years                                                                            
    ≥45                                 29         11 (37.93)               18 (62.07)               
    \<45                                31         10 (32.26)               21 (67.74)               0.645
  Sex                                                                                                
    Female                              50         19 (38.00)               31 (62.00)               0.468^[a](#tfn9-ol-0-0-6694){ref-type="table-fn"}^
    Male                                10         2 (20.00)                8 (80.00)                
  Pathological tumor size, cm                                                                        
    \>2                                 14         8 (57.14)                6 (42.86)                0.096^[a](#tfn9-ol-0-0-6694){ref-type="table-fn"}^
    ≤2                                  46         13 (28.26)               33 (71.74)               
  Underlying Hashimoto\'s thyroiditis                                                                
    Present                             19         5 (26.32)                14 (73.68)               0.337
    Absent                              41         16 (39.02)               25 (60.98)               
  Multifocality                                                                                      
    Present                             16         7 (43.75)                9 (56.25)                0.392
    Absent                              44         14 (31.82)               30 (68.18)               
  Extrathyroidal extension                                                                           
  Present                               17         8 (47.06)                9 (52.94)                0.218
  Absent                                43         13 (30.23)               30 (69.77)               
  Thyroid capsular invasion                                                                          
    Present                             30         15 (50.00)               15 (50.00)               0.015
    Absent                              30         6 (20.00)                24 (80.00)               
  BRAF mutation                                                                                      
    Positive                            29         10 (34.48)               19 (65.52)               0.935
    Negative                            31         11 (35.48)               20 (64.52)               

P-value using χ^2^ test continuity correction. LNM, lymph node metastasis; FVPTC, follicular variant papillary thyroid cancer; BRAF, B-Raf proto-oncogene; cN0, subclinical nodal disease.

###### 

Univariate analyses of associations between central LNM and clinicopathological characteristics in patients with AVPTC.

  Clinicopathological characteristic    Total, n   Central LNM (+), n (%)   Central LNM (−), n (%)   P-value
  ------------------------------------- ---------- ------------------------ ------------------------ -----------------------------------------------------
  Total number                          16         12                       4                        
  Age at diagnosis, years                                                                            
    ≥45                                   5        4 (80.00)                1 (20.00)                
    \<45                                11         8 (72.73)                3 (27.27)                0.755^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
  Sex                                                                                                
    Female                              12         10 (83.33)               2 (16.67)                0.245^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    Male                                  4        2 (50.00)                2 (50.00)                
  Pathologic tumor size, cm                                                                          
    \>2                                   7        7 (100.00)               0 (0.00)                 0.088^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    ≤2                                    9        5 (55.56)                4 (44.44)                
  Underlying Hashimoto\'s thyroiditis                                                                
    Present                               7        5 (71.43)                2 (28.57)                1.000^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    Absent                                9        7 (77.78)                2 (22.22)                
  Multifocality                                                                                      
    Present                               7        5 (71.43)                2 (28.57)                1.000^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    Absent                                9        7 (77.78)                2 (22.22)                
  Extrathyroidal extension                                                                           
    Present                               5        4 (80.00)                1 (20.00)                1.000^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              11         8 (72.73)                3 (27.27)                
  Thyroid capsular invasion                                                                          
    Present                               5        4 (80.00)                1 (20.00)                1.000^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    Absent                              11         8 (72.73)                3 (27.27)                
  BRAF mutation                                                                                      
    Positive                            13         10 (76.92)               3 (23.08)                1.000^[a](#tfn10-ol-0-0-6694){ref-type="table-fn"}^
    Negative                              3        2 (66.67)                1 (33.33)                

P-value using Fisher\'s exact test. LNM, lymph node metastasis; AVPTC, aggressive variant papillary thyroid cancer; BRAF, B-Raf proto-oncogene.

[^1]: Contributed equally
